News Releases

News Releases
Events
Presentations

Year

November 5, 2024

Bioventus Reports Third Quarter Financial Results

Q3 Revenue Advanced by 15.0% , Fourth Straight Quarter of Double Digit Organic* Growth Q3 Gross Margin Expanded 200 bps Q3 Cash from Operations of $10.3 million , an Increase of $18.6 million Compared to Previous Year DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc.

October 29, 2024

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday,

October 1, 2024

Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Advanced Rehabilitation business of its subsidiary, Bioness, to

August 7, 2024

Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth

August 6, 2024

Bioventus Reports Second Quarter Financial Results

Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9% Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bps Cash from Operations of $15.2 million Increased 40.5% Raising Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities

July 30, 2024

Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024

DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August

May 7, 2024

Bioventus Reports First Quarter Financial Results

Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities Accelerated First Quarter Revenue Growth by 8.7% , Organic Growth* by 15.3% Gross Margin Expanded 620 bps and Adjusted Gross Margin* 190 bps DURHAM, N.C., May 07, 2024 (GLOBE

April 29, 2024

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7,

March 12, 2024

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

Accelerated fourth quarter sales growth to 7.6% , organic growth* of 14.3% Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical device industry Provides full-year 2024 financial guidance reflecting enhanced

March 4, 2024

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 126